[1] |
Pizzato M, Li M, Vignat J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. Lancet Diabetes Endocrinol, 2022, 10(4):264-272.
|
[2] |
Chung AY, Tran TB, Brumund KT, et al. Metastases to the thyroid: a review of the literature from the last decade[J]. Thyroid, 2012, 22(3):258-268.
doi: 10.1089/thy.2010.0154
pmid: 22313412
|
[3] |
Cheung AY, Donner L, Capen C. Metastatic adenocarcinoma of the uterine cervix to the thyroid gland[J]. Clin Oncol (R Coll Radiol), 2000, 12(1):60-61.
|
[4] |
Moghaddam PA, Cornejo KM, Khan A. Metastatic carcinoma to the thyroid gland: a single institution 20-year experience and review of the literature[J]. Endocr Pathol, 2013, 24(3):116-124.
doi: 10.1007/s12022-013-9257-8
pmid: 23872914
|
[5] |
Cipriani NA, Agarwal S, Dias-Santagata D, et al. Clear cell change in thyroid carcinoma: a clinicopathologic and molecular study with identification of variable genetic anomalies[J]. Thyroid, 2017, 27(6):819-824.
doi: 10.1089/thy.2016.0631
pmid: 28293986
|
[6] |
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016,44:51-60.
|
[7] |
Ghossein CA, Khimraj A, Dogan S, et al. Metastasis to the thyroid gland: a single-institution 16-year experience[J]. Histopathology, 2021, 78(4):508-519.
|
[8] |
Saito Y, Sugitani I, Toda K, et al. Metastatic thyroid tumors: ultrasonographic features, prognostic factors and outcomes in 29 cases[J]. Surg Today, 2014, 44(1):55-61.
doi: 10.1007/s00595-013-0492-x
pmid: 23355002
|
[9] |
Yildirim Simsir I, Cetinkalp S, Kabalak T. Review of factors contributing to nodular goiter and thyroid carcinoma[J]. Med Princ Pract, 2020, 29(1):1-5.
doi: 10.1159/000503575
pmid: 31542786
|
[10] |
Heffess CS, Wenig BM, Thompson LD. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases[J]. Cancer, 2002, 95(9):1869-1878.
doi: 10.1002/cncr.10901
pmid: 12404280
|